Loading clinical trials...
Loading clinical trials...
Evaluating the Role of EMpagliflozin on the Rate of Post-Operative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery: a Double-blind Placebo-controlled Randomized Clinical Trial
Conditions
Interventions
Empagliflozin 10 MG
Placebo
Locations
2
Iran
Tehran Heart Center
Tehran, Iran
Rajaie Cardiovascular Medical & Research Center
Tehran, Iran
Start Date
November 7, 2023
Primary Completion Date
December 30, 2024
Completion Date
December 30, 2024
Last Updated
November 22, 2023
NCT07451522
NCT07331558
NCT07060937
NCT06726239
NCT07031128
NCT06645327
Lead Sponsor
Rajaie Cardiovascular Medical and Research Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions